Patent strengthens global intellectual property protection for QTORIN™ rapamycin, Palvella's lead product candidate from the QTORIN™ platform, in development for serious, rare skin diseases and vascular malformations with no FDA-approved therapies

Patent protection extends into 2038

QTORIN™ rapamycin has previously been granted European Orphan Drug Designation for the treatment of microcystic lymphatic malformations, potentially providing 10 years of market exclusivity in the European Union upon approval

There are currently no approved therapies in the European Union for microcystic lymphatic malformations 

WAYNE, Pa., March 16, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. ("Palvella" or "the Company") (NASDAQ:PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that the European Patent Office (EPO) has issued European Patent No. 3565520, which includes claims covering QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin), the Company's lead product candidate from the QTORIN™ platform. The patent provides protection for anhydrous topical compositions and methods of use for QTORIN™ rapamycin, including for the treatment of microcystic lymphatic malformations, venous malformations, and other diseases associated with dysregulation of the mammalian target of rapamycin (mTOR) pathway.